视网膜母细胞瘤保眼治疗中白内障的危险因素
这项回顾性单中心队列研究纳入2017年1月至2021年6月接受保眼治疗的视网膜母细胞瘤患眼,随访平均27.6个月,184只眼中31只(16.8%)发生白内障。多因素分析显示较高的眼压、每个动脉内化疗周期较高的美法仑剂量及玻璃体内化疗周期数增加是白内障的独立危险因素。
要点
- 保眼治疗后白内障发生率为16.8%(31/184眼)。
- 每个动脉内化疗周期美法仑剂量较高与白内障风险独立相关(p=0.001)。
- 玻璃体内化疗周期数增加是白内障的独立危险因素(p=0.04)。
核心结论
- 反复动脉内化疗和/或玻璃体内化疗使用美法仑是诱导白内障形成最常见的保眼治疗。
- 美法仑的毒性作用是白内障发生的关键因素,表现为白内障发生与美法仑剂量相关。
研究设计与样本
- 回顾性单中心队列研究,纳入2017年1月至2021年6月诊断为视网膜母细胞瘤并接受保眼治疗的患者。
- 共纳入184只眼,随访平均27.6个月,主要结局为随访结束时白内障。
主要发现
- 184只眼中31只(16.8%)在平均27.6个月随访期间发生白内障。
- 白内障组与对照组在侧别、性别和疾病分期方面相似。
- 白内障组更常见内生型视网膜母细胞瘤(p=0.02)和更高的眼压(p=0.001)。
- 单因素Fine-Gray竞争风险回归显示,生长模式(p=0.01)、眼压(p=0.01)、动脉内化疗周期数(p=0.001)、每个动脉内化疗周期美法仑剂量(p=0.001)和玻璃体内化疗周期数(p=0.001)与白内障发生相关。
- 多因素分析显示,较高的眼压(p=0.003)、每个动脉内化疗周期较高的美法仑剂量(p=0.001)和玻璃体内化疗周期数增加(p=0.04)是白内障的独立危险因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the risk factors for cataract following eye-preserving therapies for retinoblastoma. METHODS: This retrospective, single-centre cohort study included patients diagnosed with retinoblastoma receiving eye-preserving therapies between January 2017 and June 2021. Cataract by the end of the follow-up was the main outcome. RESULTS: Cataract was found in 31 of 184 (16.8%) included eyes during a mean follow-up of 27.6 months. The cataract and control groups were similar regarding patients' laterality, sex and disease stage. Eyes in the cataract group were more likely to present with endophytic retinoblastoma (p=0.02) and greater intraocular pressure (p=0.001). Competing risk regression analysis (univariate Fine-Gray model) showed that the growth pattern (p=0.01), intraocular pressure (p=0.01), number of intra-arterial chemotherapy (IAC) cycles (p=0.001), melphalan dose per IAC cycle (p=0.001) and number of intravitreous chemotherapy (IvitC) cycles (p=0.001) were associated with cataract occurrence. Multivariate analysis included higher intraocular pressure (p=0.003), a higher melphalan dose per IAC cycle (p=0.001) and an increasing number of IvitC cycles (p=0.04) as independent risk factors for cataract. CONCLUSIONS: Repeated IAC and/or IvitC with melphalan were the most common eye-preserving therapies that induced cataract formation. The toxic effect of melphalan was an essential factor in cataract development, as indicated by the association of cataract occurrence with the melphalan dose.
引用
- Jia S, Wen X, Yu J, et al. Risk factors for cataract in retinoblastoma management. Br J Ophthalmol. 2024. PMID: 37068919. doi:10.1136/bjo-2022-321723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。